Invivo Therapeutics (NVIV) files for Chapter 11 bankruptcy

Invivo Therapeutics (NASDAQ: NVIV) disclosed:

On February 1, 2024, after considering all strategic alternatives, InVivo Therapeutics Holdings Corp. and its subsidiary InVivo Therapeutics Corporation (together, the “Company”) filed voluntary petitions (the “Voluntary Petitions”) for relief under the provisions of Chapter 11 of Title 11 of the United States Code (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Court”). The bankruptcy case is being administered under the caption In re InVivo Therapeutics Holdings Corp., et al. The Company intends to continue to operate as a “debtor-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Code and orders of the Court.

In connection with the Voluntary Petitions, the Company also filed customary motions with the Court seeking approval of continuing business practices and a potential sale of the Company’s assets.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• BIGG Digital Assets to rename as Surge Digital, consolidate shares
• Nuvectis Pharma (NVCT) files $200M mixed shelf